Kalaris Therapeutics opened higher at $1.93, compared with its previous close of $1.90. In the last trading session, the stock traded between $1.66 and $1.95. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Kalaris Therapeutics is now worth
$ 14.43
Resulting in a loss of
$ 85.57 (85.57%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.25 (-12.89%)
Day High
$1.95
Day Low
$1.66
Day Open
$1.93
Prev Close
$1.90
Volume
1,85,998
1W Return
-19.07%
1M Return
-25.95%
3M Return
-58.10%
6M Return
-65.01%
1Y Return
-67.36%
Fundamentals
Market Cap ($ Mn)
39
PE Ratio
-
PB Ratio
1.66
PEG Ratio
-
ROE
-153.98%
ROCE
-60.04%
EPS (TTM)
-
Investment Returns
1 Week
-19.07%
1 Month
-25.95%
3 Months
-58.10%
6 Months
-65.01%
9 Months
-82.83%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
Kalaris Therapeutics Q3 Results: Loss narrows 28% YoY to $(0.46)
Loss per share narrowed to $(0.46) from $(0.64) YoY. Result beat analyst consensus of $(0.51) by 9.8%. Year-over-year improvement in losses stood at 28.13%.
2 days ago
31Aug
Kalaris Therapeutics to present at Morgan Stanley healthcare conference
Kalaris Therapeutics management to speak at Morgan Stanley conference on September 15, 2026. CEO Andrew Oxtoby and CMO Matthew Feinsod will lead the fireside chat in New York. Company is advancing TH103, a dual-action anti-VEGF therapeutic, in Phase 1b/2 trials for nAMD.
Kalaris Therapeutics delivered a second-quarter EPS of $(0.48), beating the $(0.49) estimate by 2.04%. This marks a 21.31% YoY improvement over the previous quarter's $(0.61) loss, signaling narrowing deficits.
3mo ago
4Aug
Abbott Cooper probes Kalaris Therapeutics board for duty breaches
Abbott Cooper PLLC investigates Kalaris Therapeutics directors for alleged fiduciary duty breaches. The probe targets shareholders who held stock continuously since before November 7, 2024. The firm operates on a contingency fee basis, requiring no upfront cost for participating investors.
3mo ago
20Jul
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer
Kalaris Therapeutics, Inc. has appointed Liisa Bayko, MBA, as its new Chief Financial Officer. Bayko joins the clinical-stage biopharmaceutical company focused on retinal diseases.
3mo ago
17Jul
Kalaris TH103 shows positive Phase 1a data in neovascular AMD
Kalaris Therapeutics announced positive Phase 1a data for TH103 in neovascular AMD, demonstrating extended treatment durability and no intraocular inflammation at the 2.5 mg dose. The study showed 41% of treatment-naïve patients went 4 months or longer without retreatment. Shares rose 17.79% following the announcement.
